Enzo Biochem, Inc.
ENZ
$1.09
-$0.02-1.80%
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.80M | 31.76M | 31.06M | -23.42M | -13.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.80M | 31.76M | 31.06M | -23.42M | -13.31M |
| Cost of Revenue | 18.97M | 19.26M | 19.50M | -6.27M | -4.69M |
| Gross Profit | 13.83M | 12.51M | 11.57M | -17.15M | -8.61M |
| SG&A Expenses | 33.55M | 34.04M | 32.40M | 15.77M | 11.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.03M | 57.35M | 55.80M | 12.04M | 9.64M |
| Operating Income | -23.22M | -25.58M | -24.74M | -35.46M | -22.95M |
| Income Before Tax | -23.32M | -25.34M | -25.02M | -33.94M | -23.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.32 | -25.34 | -25.02 | -33.94 | -23.61 |
| Earnings from Discontinued Operations | 55.88M | 49.65M | 45.31M | -13.71M | -13.71M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.57M | 24.31M | 20.29M | -45.58M | -35.24M |
| EBIT | -23.22M | -25.58M | -24.74M | -35.46M | -22.95M |
| EBITDA | -21.43M | -23.43M | -22.06M | -32.69M | -20.10M |
| EPS Basic | 0.67 | 0.50 | 0.41 | -0.93 | -0.72 |
| Normalized Basic EPS | -0.29 | -0.32 | -0.32 | -0.44 | -0.30 |
| EPS Diluted | 0.67 | 0.50 | 0.41 | -0.93 | -0.73 |
| Normalized Diluted EPS | -0.29 | -0.32 | -0.32 | -0.44 | -0.30 |
| Average Basic Shares Outstanding | 199.22M | 197.46M | 195.99M | 195.43M | 194.76M |
| Average Diluted Shares Outstanding | 199.22M | 197.46M | 195.99M | 195.43M | 194.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
